IL2 and melanoma: Therefore, the clinical application of IL-2 therapy for the treatment of cancer patients is limited due to its toxicity and the activation of Treg cells; ICIs have taken its place as first-line immunotherapy for the treatment of metastatic RCC and melanoma.